Cilostazol may improve prognosis in patients with diabetes and lower extremity PAD without increasing bleeding risk.
Does cilostazol improve the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus?
Cilostazol may improve outcomes in patients with diabetes and lower extremity PAD without increasing bleeding risk.
Absolute Event Rate: 0% vs 0%
In patients with diabetes and lower extremity PAD, cilostazol may improve the prognosis without increasing the risk of bleeding. These findings provide epidemiological evidence for better PAD outcomes in patients with diabetes, although further research is required to elucidate the underlying mechanisms.
Moon et al. (Mon,) reported a other. Cilostazol may improve prognosis in patients with diabetes and lower extremity PAD without increasing bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: